Sachin Wani
University of Colorado Denver/Anschutz Medical Campus, CO·Medicine & Clinical Research
Esophageal adenocarcinoma, a cancer of the food pipe, is one of the fastest-rising cancers in the United States. It is often found late and has a very poor 5-year survival rate.
- Fields
Medicine & Clinical Research
Public Health & Epidemiology
- Topics
Barrett's esophagus
low-grade dysplasia
esophageal adenocarcinoma
- Grants
- 1 known grant, through Apr 2027
What they work on
- Compare rates of progression to high-grade dysplasia or esophageal adenocarcinoma between surveillance endoscopy and endoscopic eradication therapy in a randomized trial of 530 patients with Barrett's esophagus and low-grade dysplasia.
- Compare patient-centered outcomes, such as health-related quality of life, between patients assigned to surveillance and those assigned to endoscopic eradication therapy.
- Determine whether TissueCypher molecular testing, p53 immunohistochemistry and wide-area transepithelial sampling (WATS) imaging improve the prediction of which low-grade dysplasia patients are at higher risk.
- Build a biorepository of tissue and other samples collected at set time points from trial participants to support future research.
More about the research
Its only known precursor is Barrett's esophagus (BE), a change in the esophagus lining caused by long-term acid reflux. BE affects 2–3% of U.S. adults. When BE shows high-grade dysplasia, meaning more abnormal precancerous cells, doctors usually remove or destroy the tissue during endoscopy. This is called endoscopic eradication therapy (EET). Low-grade dysplasia (LGD) is a milder and much more common finding that carries lower cancer risk. For LGD, it is unclear whether the costs and complications of EET are worth it, or whether periodic monitoring with endoscopy is enough.
Why it matters
Many people with chronic acid reflux develop Barrett's esophagus with low-grade dysplasia, a condition that can progress to deadly esophageal cancer. This trial could tell doctors whether these patients do better with endoscopic treatment or with monitoring alone. The answer could spare patients unneeded procedures or help catch cancer earlier. Validated biomarkers could also help identify which patients need treatment, guiding care for thousands of patients each year.
Known grants
From NIH and NSF research grants. Labs often have other funding we can't see.
Closest labs
Daysha Ferrer Torres
University of Colorado Denver/Anschutz Medical Campus, CO·Medicine & Clinical Research·Early-career
Compare molecular profiles and acid/bile injury responses of esophageal cells from African American and European American donors at the single-cell level, using primary tissue and stem cell-derived cultures.
Calies Menard-Katcher
University of Colorado Denver/Anschutz Medical Campus, CO·Medicine & Clinical Research
Compare dupilumab, an antibody drug that blocks inflammatory and scarring pathways, with swallowed fluticasone in a pilot randomized trial of adults and children with fibrostenotic eosinophilic esophagitis.
Sarah Psutka
University of Washington, WA·Medicine & Clinical Research
Test whether weekly in-clinic true acupuncture before intravesical therapy reduces urinary symptoms more than sham acupuncture or a waitlist control, using the EORTC QLQ-NMIBC24 questionnaire at weeks 3, 6 and 12.
The school
University of Colorado Denver/Anschutz Medical Campus: 41 labs on PI Pages, $766M a year on research, 205 research doctorates a year.
More about University of Colorado Denver/Anschutz Medical Campus
Reach out
A start for your email. Fill in the brackets.